Form 4: ZEVRA Executive Sells Shares After RSU Vesting

ZEVRA Therapeutics SVP of Finance, Timothy J. Sangiovanni, reported the vesting and subsequent sale of company common stock.

Summary

• Timothy J. Sangiovanni, SVP, Finance & Corp Controller of ZEVRA THERAPEUTICS, INC., reported transactions involving company common stock.
• On January 30, 2026, 6,333 restricted stock units (RSUs) vested and settled into common stock.
• On the same day, 1,750 shares of common stock were sold at a weighted average price of $8.824 per share, under a Rule 10b5-1 plan adopted on March 28, 2025.
• On January 31, 2026, an additional 11,666 restricted stock units (RSUs) vested and settled into common stock.
• Following these transactions, Sangiovanni beneficially owns 20,924 shares of common stock directly and 11,668 derivative securities (RSUs).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine executive compensation and a pre-planned sale under a 10b5-1 plan, with no significant positive or negative implications for the company's operational or financial performance.

Positives

• Vesting of 6,333 restricted stock units on January 30, 2026, and 11,666 restricted stock units on January 31, 2026, indicates continued compensation and retention of a key executive.
• The transactions were made pursuant to a Rule 10b5-1 plan, suggesting a pre-planned and automated sale, which can mitigate concerns about opportunistic insider selling.

Negatives

• The sale of 1,750 shares of common stock by a Senior Vice President, Finance & Corporate Controller, could be perceived as a slight reduction in direct equity exposure, although it is a relatively small portion of the total shares acquired through vesting.

Future Outlook

NA

Management Comments

• The transaction was executed in multiple trades at prices ranging from $8.62 to $8.995.
• The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those executed under a 10b5-1 plan following RSU vesting, are common across industries and typically reflect executive compensation practices rather than a specific industry trend or strategic move.

Stakeholder Impact

• Shareholders: Minor impact as it is a routine insider transaction. The sale is relatively small compared to the total shares outstanding and was pre-planned.
• Management: The vesting and sale are part of the executive's compensation structure.

Next Steps

• Remaining two-thirds of the first RSU grant will vest and settle in equal annual installments after January 30, 2026, subject to continued service.
• Remaining one-third of the second RSU grant will vest and settle on January 31, 2027, subject to continued service.

Key Dates

Keywords

ZEVRA Therapeutics, ZVRA, Form 4, Insider Trading, Stock Sale, RSU Vesting, Timothy J. Sangiovanni, 10b5-1 Plan, Common Stock